-

07:02:57 PM

LMDX Stock News

LMDX - LumiraDx Limited

03/21/23 7:26 AM

Nasdaq : LMDX

LumiraDx Reports Fourth Quarter and Full Year 2022 Results

LumiraDx Limited (NASDAQ: LMDX), a next-generation point of care (POC) diagnostics company, today announced financial results for its fourth quarter and full year ended December 31, 2022. Full year 2022 revenues of $254.5 million. Q4 2022 revenue of

RHEA-AI

neutral

03/14/23 8:03 AM

Nasdaq : LMDX

earnings

LumiraDx to Announce Fourth Quarter and Full Year 2022 Financial Results and Host Quarterly Conference Call on March 21

LumiraDx Limited (Nasdaq: LMDX), a next-generation point of care (POC) diagnostics company, announced it will release its fourth quarter and full year 2022 financial results on Tuesday, March 21 st, 2023. On the day of the release, LumiraDx will host a

RHEA-AI

neutral

03/03/23 9:00 AM

Nasdaq : LMDX

conferences

LumiraDx to Present at Raymond James Institutional Investors Conference

LumiraDx Limited (Nasdaq: LMDX) (the “Company”) today announced that Chief Financial Officer, Dorian LeBlanc, will be presenting at the Raymond James Institutional Investors Conference on Tuesday, March 7 th, 2023 at 4:35pm ET. Webcast link below.

RHEA-AI

neutral

02/17/23 4:15 PM

Nasdaq : LMDX

LumiraDx Regains Compliance with Nasdaq Continued Listing Requirements

LumiraDx Limited (Nasdaq: LMDX) (the “Company”) today announced that it has received confirmation from The Nasdaq Stock Market LLC (“Nasdaq”) that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5450(a)(1). On

RHEA-AI

neutral

02/06/23 8:00 AM

Nasdaq : LMDX

covid-19

LumiraDx Receives FDA Emergency Use Authorization and UK CTDA Approval for its Fast Lab Solutions Multiplex COVID and Influenza Molecular Assay

LumiraDx SARS-CoV-2 & Flu A/B RNA STAR Complete assay receives Emergency Use Authorization from the FDA along with being successfully validated by the UK Health Security Agency (UKHSA) under the Coronavirus Test Device Approvals (CTDA) process. This multiplex test utilizes the innovative qSTAR

RHEA-AI

neutral

01/31/23 4:30 PM

Nasdaq : LMDX

LumiraDx Announces Commercial Shipment of its Point of Care NT-proBNP Test in Europe, Supporting Heart Health Checks in UK

Run on the highly portable LumiraDx Platform, the LumiraDx NT-proBNP test is a quantitative, fingerstick blood assay designed for near-patient testing with lab-comparable results in 12 minutes. It is the only fingerstick NT-proBNP test currently commercially available. The LumiraDx NT-proBNP test

RHEA-AI

neutral

01/31/23 4:15 PM

Nasdaq : LMDX

LumiraDx Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency

LumiraDx Limited (Nasdaq: LMDX)(the “Company”) today announced that it has received notification (the “Notification”) from The Nasdaq Stock Market LLC that it is not in compliance with the minimum bid price requirement in Nasdaq Listing Rule 5450(a)(1)

RHEA-AI

neutral

12/14/22 3:19 AM

Nasdaq : LMDX

LumiraDx Announces New Investment for Ongoing Development of its Point of Care Molecular Tuberculosis Test

LumiraDx Limited (Nasdaq: LMDX), a next-generation point of care diagnostics company, today

RHEA-AI

neutral

12/08/22 3:01 AM

Nasdaq : LMDX

Latest Clinicians’ U.S. Survey Identifies Point of Care Testing (POCT) as a Way to Address Healthcare Bandwidth Pressures and Anticipates Future Growth of POCT in Community Testing Centers

LumiraDx Limited (Nasdaq: LMDX), a next-generation point of care diagnostics company, today announced findings from its

RHEA-AI

neutral

11/14/22 2:58 AM

Nasdaq : LMDX

LumiraDx Continues Commercial Expansion of its Rapid Microfluidic Immunoassay HbA1c Test

Now Available in Europe, parts of the Middle East, Asia, Latin America, and Africa Early customers include GP offices and other community-based healthcare settings Latest figures, released as part of World Diabetes Day, reveal that 1 in 10 adults are now living with diabetes and nearly half are

RHEA-AI

very positive